Forbion catering to abundance of maturing European biotechs with new growth fund

Forbion closes first €185M of planned €250M Growth Opportunities Fund

Forbion’s launch of a new late-stage and crossover fund reflects the growing need for capital among maturing European biotechs, including those that are past the proof-of-concept stage and are seeking liquidity.

Over the past few years, most European life sciences VCs have been raising bigger early-stage funds that have poured larger amounts of cash into start-ups. Companies in that category are now coming of age:

Read the full 643 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE